The shadow of generic challenges has long loomed around copyright’s iconic drug, PDE5 Inhibitor, sparking questions about the future of related pharmaceutical stakes. While first times saw impressive knockoff returns, the patent lapse has opened the way for discounted substitutes, potentially lowering profitability and posing a real hazard for in